Cardiovascular and Gastrointestinal Effects of Etoricoxib in the Treatment of Osteoarthritis: A Systematic Review and Network Meta-analysis

Dam Kim¹, Soo-Kyung Cho¹, Seoung Wan Nam¹, Hyuk Hee Kwon¹, Sun-Young Jung², Chan Hong Jeon³, Seul Gi Im⁴, Dalho Kim⁵, Eun Jin Jang⁵, Yoon-Kyoung Sung¹
¹Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, ²College of Pharmacy, Chung-Ang University, Seoul, ³Division of Rheumatology, Department of Internal Medicine, Soon Chun Hyang University Bucheon Hospital, Bucheon, ⁴Department of Statistics, Kyungpook National University, Daegu, ⁵Department of Information Statistics, Andong National University, Andong, Korea

Objective. To estimate the cardiovascular (CV) and gastrointestinal (GI) risks of etoricoxib in the treatment of osteoarthritis (OA) compared to a placebo and other non-steroidal anti-inflammatory drugs (NSAIDs).

Methods. A systematic review of randomized, controlled trials (RCTs) of etoricoxib were performed. Bayesian network meta-analysis was used over a duration of 12 weeks. The incidence of CV and GI events for a duration ≥ 26 weeks were also tabulated and presented using descriptive statistics.

Results. From this search, 10 studies were identified. Of these, 6 and 5 RCTs that measured the CV and GI events at 12 weeks were included in meta-analysis. They showed that etoricoxib did not increase the CV events compared to the placebo or NSAIDs during the 12 week period (odds ratio [OR] = 0.59 compared to celecoxib, OR = 0.89 with ibuprofen, OR = 0.70 with placebo, and OR = 2.16 with naproxen). The risk of GI events was comparable to that of most comparators, with the exception of naproxen, which had a significantly lower risk of GI events (OR = 0.18) during the 12 week period. For a duration ≥ 26 weeks, the incidence of CV and GI events with etoricoxib increased with increasing duration.

Conclusion. Etoricoxib is an alternative short-term treatment option for OA, showing comparable CV and GI complications to other NSAIDs. Nevertheless, further studies will be needed to elucidate the long-term safety of etoricoxib in the treatment of OA. (J Rheum Dis 2017;24:293-302)

Key Words. Anti-inflammatory agents, non-steroidal, Etoricoxib, Osteoarthritis, Safety

INTRODUCTION

Osteoarthritis (OA) is the most common joint disorder, affecting 70% of individuals older than 55 years [1]. For treatment of OA, non-steroidal anti-inflammatory drugs (NSAIDs) are the mainstay for reducing pain and inflammation, although detailed recommendations are different according to treatment guidelines [2-5]. However, since OA is a chronic disease and affects mainly patients with advanced age, safety profiles of medications are as important as their effectiveness.

Non-selective NSAIDs, which inhibit both cyclooxygenase (COX)-1 and COX-2, are well known to cause severe gastrointestinal (GI) adverse events [6,7]. With many risk factors for development of GI adverse events such as old age, concomitant use of other medication for comorbidities, and long duration of NSAID use, OA patients have increased risk of GI adverse events [6]. Therefore, the use of selective COX-2 inhibitors, which are safer in terms of GI adverse events, has been quickly adopted for treatment of OA [8]. However, another safety concern arose because of the high selectivity of COX-2, which might be associated with higher risk of cardiovascular (CV) events [9-11].

Etoricoxib, which is a relatively new COX-2 inhibitor, is known to be an effective and safe treatment option for ar-
In this study, we aimed to estimate CV and GI risks of etoricoxib in treatment of OA compared with placebo and other NSAIDs according to duration and dose of medication.

**MATERIALS AND METHODS**

**Literature search**

We performed a systematic literature review of randomized controlled trials (RCTs) of etoricoxib in patients with OA of the hand, knee, hip, or spine. A computerized search of electronic databases from their inception to September 12, 2017 was performed in MEDLINE, EMBASE, and CENTRAL database of Cochrane Library. Search terms are provided in Supplementary Table 1. Our search included only human subjects and articles written in English.

**Selection criteria**

RCTs that evaluated the CV or GI safety of etoricoxib compared with placebo or other NSAIDs in adults with OA of any site for a duration of six weeks or longer were included in this study. Eligible studies included those where osteoarthritis was diagnosed based on clinical decision. We excluded trials that studied post-operative safety and trials that included patients with inflammatory arthritis such as rheumatoid arthritis. We also excluded studies that compared the CV and GI safety of etoricoxib and opioids. Finally, we excluded trials that did not report relevant safety outcomes adjudicated by independent expert Case Review Committees. Three authors (DK, S.W.N., and H.H.K.) independently extracted data and assessed bias; any disagreement was resolved by discussion and consensus.

**Outcome measures**

The outcomes of interest were thrombotic CV adverse events and upper GI adverse events during treatment with etoricoxib or a comparator. We examined the numbers of patients with thrombotic CV adverse events such as myocardial infarction and ischemic cerebrovascular accident in cardiovascular, cerebrovascular, and peripheral vascular beds. We also extracted the numbers of patients with upper GI adverse events including perforation, ulcer, and bleeding. All potential serious CV and GI adverse events included in this analysis were adjudicated by separate, blinded expert case review committees.

**Data extraction and assessment of bias**

We extracted participant characteristics of age, site of OA, and treatment duration, as well as aspects of the study including number of patients and dose and times per day. In addition, interventions were divided into an etoricoxib group and a comparators group including placebo, diclofenac, celecoxib, ibuprofen, and naproxen. In order to evaluate safety outcomes, use of low dose aspirin and gastroprotective agents was noted. Relevant safety outcomes were collected as number of CV and GI adverse events during treatment duration.

For this study, we utilized the Cochrane Collaboration’s tool for assessment of risk of bias in order to assess study quality [15]. Each study was scored as high risk, low risk, or unclear risk of bias in seven domains: random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data, selective reporting, and other bias. Other bias was including design-specific risks of bias, early stopping for benefit, severe baseline imbalances, and inappropriate influence of funders.

Three authors (DK, S.W.N., and H.H.K.) independently extracted data and assessed bias; any disagreement was resolved by discussion and consensus.

**Ethical considerations**

The study protocol was approved by the Institutional Review Board (IRB) of Hanyang University (IRB no. 2016-06-008).

**Statistical analysis**

This study focused on relatively rare adverse events. In general, if there are zero cells in dichotomous outcome, a continuity correction is required to calculate the odds ratio (OR) or relative risk. However, corrections for zero cell counts are not necessary when using Peto’s method [16]. Because of zero cell counts of CV adverse events and GI adverse events, we considered the Peto’s OR as the effect size.

To compare the risk of adverse events for etoricoxib with the risk for each NSAID or placebo with therapy duration.
of 12 weeks, network meta-analysis was performed. Network meta-analysis is a method of combining direct evidence and indirect evidence to estimate the pairwise treatments effect, and frequentist or Bayesian approaches are possible. The Bayesian method combines likelihood with a prior distribution to obtain a posterior probability distribution [17] and allows probability statements to be made directly regarding quantity of interest; for example, OR is more than 1 \( (P[OR > 1]) \) [18]. In addition, the Bayesian hierarchical random-effects model was used to account for the clinical and methodological heterogeneity between included studies. We assumed a normal likelihood distribution for the logarithm of Peto’s OR and noninformative uniform prior distribution for standard deviation between trials.

There are two assumptions for conducting network meta-analysis. The similarity assumption requires that the included study populations are similar in effect modifiers such as age, disease severity, and disease duration [19]. We compared the baseline characteristics of each study and the adverse event incidence in the etoricoxib group to verify the similarity assumption. The consistency assumption that the direct estimate is consistent with indirect estimates is another main assumption in a network meta-analysis, and this assumption was assessed using the node-splitting method [20].

We presented the posterior median and 95% credible interval (CrI) for OR and the posterior probability that OR is more than 1 \( (P) \). \( P \) of at least 90% signifies increased risk of etoricoxib over NSAIDs or placebo, and \( P \) less than 10% indicates that etoricoxib had a lower risk than NSAIDs or placebo. The parameters were estimated using the Markov Chain Monte Carlo (MCMC) algorithm in WinBUGS Version 1.4.3 (MRC Biostatistics Unit, Cambridge, UK), and the convergence of the MCMC algorithm was assessed using trace plot, autocorrelation plot, and Gelman-Rubin statistics. We discarded the first 10,000 iterations in order to eliminate the initial value effect, and 50,000 iterations were performed in two chains for estimation of the posterior distribution. In the sensitivity analysis, we applied inverse-gamma or normal noninformative prior distribution for the variance between trials in order to assess the robustness of results.

In addition, we performed subgroup analysis in patients with OA of the hip and knee joint to evaluate whether etoricoxib had different adverse events compared with patients with OA of any site. Moreover, subgroup analysis according to dose of etoricoxib was also performed to identify the dose effect of etoricoxib for CV and GI events. Since the number of studies involving treatment duration of 26 weeks or longer was small, and studies did not meet the homogeneity assumption, the incidence of CV and GI events in therapy duration of 26 weeks or longer was tabulated and presented using descriptive statistics.

**RESULTS**

**Study characteristics**

Among 371 RCTs searched using multiple electronic searches, 48 full texts were assessed for eligibility after excluding 323 studies by screening title and abstract. A final 10 studies were included in our study after further reviewing full texts [21-30]: eight were excluded because they were not RCTs, three were without peer review, seven involved non-OA patients, one did not involve etoricoxib, 16 reported no outcome of interest, two did not utilize adequate comparators, and one was excluded for other reasons (Figure 1).
We included 10 trials of etoricoxib compared with placebo or one of four types of NSAID: celecoxib, diclofenac, ibuprofen, and naproxen, involving 12,588 participants. The trial patient sample size varied from 239 to 7,111, and the mean age of subjects ranged from 58.3 to 63.7 years. Among them, 6 and 5 RCTs were found that measured CV and GI events at 12 weeks for inclusion, hence we synthesized data from these studies as base case analyses. Four studies had follow-up duration longer than 26 weeks, while the heterogeneity in the length of follow-up and data reporting, led us to the decision not to perform a quantitative analysis. The other study was not included in either analysis because this RCT by Gottesdiener et al. [25] was conducted with placebo- and active comparator in order; Part I (6 weeks) with placebo and Part 2 (8 weeks) with diclofenac (Table 1, Supplementary Table 1). Characteristics of studies included in this analysis

<table>
<thead>
<tr>
<th>Study</th>
<th>Mean patient age (yr)</th>
<th>Site of osteoarthritis included</th>
<th>Treatment duration</th>
<th>Etoricoxib group</th>
<th>Comparator</th>
<th>Other medication allowed</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Number Dose* times Medication Number Dose* times</td>
<td>Low dose aspirin</td>
<td>Gastro-protective agents</td>
</tr>
<tr>
<td>Baraf et al., 2007 [21]</td>
<td>63.7</td>
<td>Knee, hip, hand, or spine</td>
<td>11 ~ 16 mo</td>
<td>3,593 90 mg *1</td>
<td>Diclofenac 3,518 50 mg *3</td>
<td>Yes Yes</td>
</tr>
<tr>
<td>Bingham et al., 2007 [22]</td>
<td>62.1</td>
<td>Knee or hip</td>
<td>26 wk</td>
<td>475 30 mg *1</td>
<td>Celecoxib 487 200 mg *1</td>
<td>Yes Unknown</td>
</tr>
<tr>
<td>Cannon et al., 2008 [23]</td>
<td>58.3</td>
<td>No description about site</td>
<td>12 wk</td>
<td>108 90 mg *1</td>
<td>Celecoxib 107 200 mg *2</td>
<td>No Unknown</td>
</tr>
<tr>
<td>Curtis et al., 2005 [24]</td>
<td>61.7</td>
<td>Knee</td>
<td>46 wk</td>
<td>198 30 mg *1</td>
<td>Placebo 117 5 mg *1</td>
<td>No Unknown</td>
</tr>
<tr>
<td>Gottesdiener et al., 2002 [25]*</td>
<td>61.3</td>
<td>Knee</td>
<td>6 wk (Part I)</td>
<td>117 5 mg *1</td>
<td>Placebo 114 10 mg *1</td>
<td>No Unknown</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>114 10 mg *1</td>
<td>Placebo 102 30 mg *1</td>
<td>No Unknown</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>112 60 mg *1</td>
<td>Placebo 112 90 mg *1</td>
<td>No Unknown</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>112 90 mg *1</td>
<td>Placebo 102 30 mg *1</td>
<td>No Unknown</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>8 wk (Part II)</td>
<td>Placebo 102 30 mg *1</td>
<td>No Unknown</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>148 90 mg *1</td>
<td>Diclofenac 102 50 mg *3</td>
<td>Yes Yes</td>
</tr>
<tr>
<td>Leung et al., 2002 [26]</td>
<td>63.2</td>
<td>Knee or hip</td>
<td>12 wk</td>
<td>224 60 mg *1</td>
<td>Naproxen 221 500 mg *2</td>
<td>Unknown</td>
</tr>
<tr>
<td>Puopolo et al., 2007 [27]</td>
<td>62.6</td>
<td>Knee or hip</td>
<td>12 wk</td>
<td>224 30 mg *1</td>
<td>Ibuprofen 213 800 mg *3</td>
<td>Yes Unknown</td>
</tr>
<tr>
<td>Reginster et al., 2007 [28]</td>
<td>62.8</td>
<td>Knee or hip</td>
<td>12 wk</td>
<td>446 60 mg *1</td>
<td>Naproxen 439 1,000 mg *1</td>
<td>Yes Yes</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>434 60 mg *1</td>
<td>Placebo 112</td>
<td>Yes Yes</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>86 wk 246 60 mg *1</td>
<td>Naproxen 404 1,000 mg *1</td>
<td>Yes Yes</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>12 wk 214 30 mg *1</td>
<td>Placebo 217 1,000 mg *1</td>
<td>Yes Yes</td>
</tr>
<tr>
<td>Wiesenhutter et al., 2005 [29]</td>
<td>61.7</td>
<td>Knee or hip</td>
<td>12 wk</td>
<td>214 30 mg *1</td>
<td>Ibuprofen 210 800 mg *3</td>
<td>Yes Yes</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Placebo 104</td>
<td>Yes Yes</td>
</tr>
<tr>
<td>Yoo et al., 2014 [30]</td>
<td>63.0</td>
<td>Knee</td>
<td>12 wk</td>
<td>120 30 mg *1</td>
<td>Celecoxib 119 200 mg *1</td>
<td>Yes Unknown</td>
</tr>
</tbody>
</table>

*This two-part, randomized controlled trial was conducted with placebo- and active comparator in order. Part I (6 weeks), patients received placebo, etoricoxib 5, 10, 30, 60 or 90 mg once daily. In Part II (8 weeks), patients received etoricoxib 30, 60 or 90 mg once daily or diclofenac 50 mg three times a day, predetermined at Part I allocation.
CV and GI Effects of Etoricoxib in Osteoarthritis

The risk of bias in the majority of domains was very low: blinding of outcome assessment domain (risk of bias “low” 10/10) and incomplete outcome data domain (risk of bias “low” 10/10). However, the risk of bias was high in the other bias domain (risk of bias “high” 10/10) since all included studies were sponsored by the pharmaceutical company that produces etoricoxib (Supplementary Figure 1).

### Risk of cardiovascular adverse events of etoricoxib

During follow-up periods, 58 and 51 CV adverse events occurred in the etoricoxib groups and comparator groups, respectively. The network of treatment comparisons from the included trials is shown in Figure 2A.

In OA of any included site, etoricoxib did not increase the risk of CV events compared with comparators during 12 weeks (OR=0.70, 95% CrI=0.12∼3.89, P=0.34 compared with placebo, OR=0.59, 95% CrI=0.03∼11.86, P=0.36 compared with celecoxib, OR=0.89, 95% CrI=0.12∼6.49, P=0.45 with ibuprofen, and OR=2.16, 95% CrI=0.19∼25.18, P=0.74 with naproxen) (Figure 3A). The results were consistent when we included studies of patients with OA of the hip or knee joints over a duration of 12 weeks (OR=0.65, 95% CrI=0.08∼4.91, P=0.33 with placebo, OR=0.99, 95% CrI=0.01∼95.15, P=0.50 with celecoxib, OR=0.84, 95% CrI=0.07∼10.07, P=0.44 with ibuprofen, OR=2.11, 95% CrI=0.14∼31.37, P=0.72 with naproxen) (Figure 3A) [26-30]. In analysis according to dose of etoricoxib, 30 mg of and 60 mg or higher dose of etoricoxib did not increase the risk of CV events compared with comparators during 12 weeks (Figure 3C). The results of sensitivity analysis using different prior distributions were consistent with the results of the base case.

After 26 weeks, the incidence of CV events in the etoricoxib group had a tendency to increase according to treatment duration (0.21% at 26 weeks, 1.14% at 11∼16 months, 2.59% at 138 weeks) (Supplementary Table 2). In addition, the incidence of CV events was more than double that found with naproxen in a study of treatment for 138 weeks (2.59% in etoricoxib vs. 1.21% in naproxen) [28]. However, among these studies, we could not find any tendency of CV event incidence with dose of etoricoxib (data not shown).

### Risks of gastrointestinal adverse events of etoricoxib

In the 10 studies included in this analysis, 40 and 67 GI adverse events occurred in the etoricoxib groups and comparator groups, respectively. The network of treatment comparisons from included trials is shown in Figure 2B.

During 12 weeks of treatment, the risk of GI events was comparable to that found with other comparators (OR=0.38, 95% CrI=0.03∼4.28, P=0.21 compared with placebo, OR=0.94, 95% CrI=0.04∼20.35, P=0.49 with celecoxib and OR=0.49, 95% CrI=0.03∼7.21, P=0.29 with ibuprofen), while the risk of GI events was significantly lower than that found with naproxen (OR=0.18, 95% CrI=0.03∼1.17, P=0.03) (Figure 4A). Among studies that included patients with OA of the lower extremities and involved treatment of 12 weeks, etoricoxib showed...
significantly lower risk of GI events compared with naproxen (OR=0.18, 95% CrI=0.01 \sim 2.73, P=0.06), while there was no significant difference compared with placebo, celecoxib, and ibuprofen (OR=0.24, 95% CrI=0.01 \sim 6.07, P=0.18 with placebo, OR=0.99, 95% CrI=0.01 \sim 162.70, P=0.50 with celecoxib, OR=0.33, 95% CrI=0.00 \sim 20.83, P=0.27 with ibuprofen) (Figure 4B) [26-30]. In analysis according to dose of etoricoxib, 30 mg of etoricoxib showed comparable risk of GI events with celecoxib, ibuprofen and placebo during 12 weeks. However, in 60 mg or higher dose etoricoxib, etoricoxib showed significantly lower risk of GI events compared with naproxen (OR=0.19, 95% CrI=0.01 \sim 3.15, P=0.07), while the risk of GI events for etoricoxib were comparable with celecoxib, ibuprofen, and placebo (Figure 4C). The results of sensitivity analysis using different prior distributions were consistent with the results of the base case.

With a treatment duration of 26 weeks or longer, the incidence of GI events in the etoricoxib group increased with treatment duration (0.21% at 26 weeks, 0% \sim 0.68% at 46 weeks, 1.34% at 11 \sim 16 months, and 1.39% at 138 weeks) (Supplementary Table 3). In addition, the incidence of GI events increased with dose of etoricoxib (0.15% in 30 mg, 1.16% in 60 mg, and 1.31% in 90 mg of etoricoxib). In a study that compared etoricoxib therapy to naproxen therapy over a treatment duration of 138 weeks, the incidence of GI events in the etoricoxib group was approximately 1/4 of that occurring in the naproxen group (1.39% in etoricoxib vs. 4.85% in naproxen) [28].

**DISCUSSION**

In this study, we reviewed the risk of CV and GI events
resulting from use of etoricoxib compared with placebo or other NSAIDs. In a relatively short treatment duration of 12 weeks, etoricoxib was found to be safe in terms of CV and GI events compared with the other treatments, irrespective of doses. In addition, the risk of GI events was significantly lower in etoricoxib compared with naproxen, which is one of the widely used non-selective NSAIDs. However, in studies with longer treatment duration, both CV and GI adverse events increased with treatment duration, although statistical significance was not confirmed.

It is well known that COX-2 inhibitors significantly reduce the risk of GI events compared to non-selective NSAIDs [6,31]. However, concern about increased risk of CV events with COX-2 inhibitors exists. Several COX-2 inhibitors have been withdrawn or not approved for use due to increased CV risk [9,32]. Researchers have determined that increased risk of CV and cerebrovascular events is associated with highly selective COX-2 inhibitors [11,33].

Etoricoxib, which is a relatively new and potent selective COX-2 inhibitor, is known to have comparable efficacy to non-selective NSAIDs and better GI safety for arthritis patients. Etoricoxib is a highly selective COX-2 inhibitor and does not inhibit COX-1 at clinical doses, resulting in significantly lower risk of GI events than found with non-selective NSAIDs [34]. However, the high selectivity of COX-2 in etoricoxib is still of concern due to potential higher risk of CV events.

This study found etoricoxib to be as safe as other comparators (placebo, celecoxib, ibuprofen, and naproxen) regarding CV events in a short treatment duration. Thus, etoricoxib is a safe alternative to non-selective NSAIDs, with comparable efficacy over a short treatment duration. Etoricoxib was also safe regarding CV events in various doses even in high dose of 60 mg or higher. However, treatment durations of 26 weeks or longer resulted in more adverse CV events. Considering that CV events significantly increased compared with placebo use from 18 months’ duration in a previous study comparing rofecoxib and placebo [9], our results that CV events of etoricoxib were significantly increased only with longer treatment duration are acceptable. Although we did not demonstrate statistical significance because of the small number of studies, the long-term CV safety of etoricoxib is very important. Patients with OA are usually older in age and likely to have several comorbidities including CV, cere-
brovascular diseases, and many other conditions that can increase the risk of CV events. Moreover, OA is a chronic disease that requires long-term medical treatment. Therefore, more research about the long-term CV safety of etoricoxib is needed, especially for OA patients.

In addition, etoricoxib was as safe as other comparators in term of GI events. Moreover, compared with naproxen, etoricoxib was significantly safer regarding GI events. This can be explained by the characteristics of naproxen, which is a non-selective NSAID with greater COX-1 selectivity. Gastrointestinal events also increased with treatment duration, and it seemed that a higher dose of etoricoxib resulted in more GI events, although the number of studies was not large enough to reach a statistical conclusion. Because OA patients are also vulnerable to GI events due to their long-term use of NSAIDs and concomitant medication such as aspirin, anti-coagulants, and steroids, the increased risk of etoricoxib when used in high doses over long durations must be confirmed.

Several points of this study are worth noting. First, we defined clear inclusion and exclusion criteria, as well as outcome assessments, in order to draw reliable conclusions. Because many of the studies reviewed had different outcome definitions, it was impossible to synthesize and produce definitive conclusions. Therefore, we adopted a strict definition that was adjudicated by independent expert case review committees. Second, different from previous studies, we presented the incidence of CV and GI events over a longer period of time according to dose and treatment duration. Although we could not demonstrate statistical significance with longer duration, we suggest the risk and significance of CV adverse events with long-term use of etoricoxib, especially in OA patients.

There were some limitations in this study. First, only 10 RCTs were included, although all RCTs conducted after the approval of etoricoxib were collected. Because of the small number of RCTs, it was not possible to divide the CV and GI events according to site and severity of occurrence. One observational study and one single arm study were included, but these studies did not describe the safety outcome of interest and so were not included [35,36]. Second, meta-analysis was performed only with studies of short duration. Since studies of relatively longer treatment duration did not adhere to the homogeneity or similarity assumption, descriptive statistics were used for qualitative analysis. However, it seems that the risk of CV and GI events increase depending on duration of etoricoxib use, and more studies are needed to conclude the long-term CV and GI safety of etoricoxib. Third, since adverse events are limited in number, meta-analysis should be performed carefully. In the classic meta-analysis, when there are no events in either arm of a study, it is omitted from the analysis as it provides no information about the relative effect [37]. In this study, we applied a Bayesian hierarchical random-effects model, which can borrow strength from other studies; thus, we included studies with no events in either arm [18]. In addition, the primary outcomes of RCTs included in this study were not safety of etoricoxib, therefore, the power of safety outcome in individual studies could be low. Fourth, although the risk of bias in studies included in this analysis was relatively low, the bias caused by sponsor is unneglectable. For an accurate and fair estimation of safety, further studies are needed in the future.

CONCLUSION

Etoricoxib showed comparable CV and GI complications to non-selective NSAIDs and can be considered as an alternative short-term treatment option for OA. However, further studies are needed to elucidate the long-term safety of etoricoxib in the treatment of OA.

ACKNOWLEDGMENTS

This research was supported by a grant of the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea (grant number: HC15C3388).

CONFLICT OF INTEREST

No potential conflict of interest relevant to this article was reported.

SUPPLEMENTARY DATA

Supplementary data can be found with this article online at http://www.jrd.or.kr and at https://doi.org/10.4078/jrd.2017.24.5.293.

REFERENCES


29. Wiesenhutter CW, Boice JA, Ko A, Sheldon EA, Murphy FT,


